Xintela AB (publ) (XINT.ST)

SEK 0.32

(-0.63%)

Total Liabilities Summary of Xintela AB (publ)

  • Xintela AB (publ)'s latest annual total liabilities in 2023 was 14.01 Million SEK , down -25.21% from previous year.
  • Xintela AB (publ)'s latest quarterly total liabilities in 2024 Q2 was 29.06 Million SEK , down -2.43% from previous quarter.
  • Xintela AB (publ) reported annual total liabilities of 18.74 Million SEK in 2022, down -9.88% from previous year.
  • Xintela AB (publ) reported annual total liabilities of 20.79 Million SEK in 2021, down -0.53% from previous year.
  • Xintela AB (publ) reported quarterly total liabilities of 29.78 Million SEK for 2024 Q1, up 112.53% from previous quarter.
  • Xintela AB (publ) reported quarterly total liabilities of 14.01 Million SEK for 2023 Q4, up 13.79% from previous quarter.

Annual Total Liabilities Chart of Xintela AB (publ) (2023 - 2013)

Historical Annual Total Liabilities of Xintela AB (publ) (2023 - 2013)

Year Total Liabilities Total Liabilities Growth
2023 14.01 Million SEK -25.21%
2022 18.74 Million SEK -9.88%
2021 20.79 Million SEK -0.53%
2020 20.9 Million SEK 169.1%
2019 7.76 Million SEK 62.91%
2018 4.76 Million SEK -53.11%
2017 10.17 Million SEK 254.85%
2016 2.86 Million SEK -9.33%
2015 3.16 Million SEK 231.24%
2014 954.29 Thousand SEK -52.34%
2013 2 Million SEK 0.0%

Peer Total Liabilities Comparison of Xintela AB (publ)

Name Total Liabilities Total Liabilities Difference
Alligator Bioscience AB (publ) 106.59 Million SEK 86.852%
Ziccum AB (publ) 6.38 Million SEK -119.396%
Modus Therapeutics Holding AB (publ) 2.35 Million SEK -494.108%
BioArctic AB (publ) 139.5 Million SEK 89.954%
Sprint Bioscience AB (publ) 34.6 Million SEK 59.498%
Mendus AB (publ) 51.22 Million SEK 72.64%
Genovis AB (publ.) 98.04 Million SEK 85.706%
Intervacc AB (publ) 21.68 Million SEK 35.355%
QuiaPEG Pharmaceuticals Holding AB (publ) 26.7 Million SEK 47.525%
Active Biotech AB (publ) 13.4 Million SEK -4.59%
Magle Chemoswed Holding AB (publ) 123.97 Million SEK 88.696%
Bio-Works Technologies AB (publ) 16.11 Million SEK 13.042%
Aptahem AB (publ) 8.99 Million SEK -55.76%
Vicore Pharma Holding AB (publ) 40.85 Million SEK 65.699%
Kancera AB (publ) 17.97 Million SEK 22.044%
Infant Bacterial Therapeutics AB (publ) 46.18 Million SEK 69.651%
Fluicell AB (publ) 8.91 Million SEK -57.207%
Saniona AB (publ) 86.08 Million SEK 83.719%
Lipigon Pharmaceuticals AB (publ) 5.15 Million SEK -171.714%
Biovica International AB (publ) 34.76 Million SEK 59.689%
Spago Nanomedical AB (publ) 11.66 Million SEK -20.115%
AcouSort AB (publ) 10.37 Million SEK -35.045%
Abliva AB (publ) 16.78 Million SEK 16.483%
Egetis Therapeutics AB (publ) 214.6 Million SEK 93.469%
Karolinska Development AB (publ) 11.56 Million SEK -21.143%
OncoZenge AB (publ) 1.69 Million SEK -724.897%
Amniotics AB (publ) 10.54 Million SEK -32.881%
2cureX AB (publ) 2.93 Million SEK -377.513%
CombiGene AB (publ) 4.15 Million SEK -237.223%
Asarina Pharma AB (publ) 4.42 Million SEK -216.652%
Calliditas Therapeutics AB (publ) 1.56 Billion SEK 99.105%
Camurus AB (publ) 414.81 Million SEK 96.621%
Corline Biomedical AB 6.78 Million SEK -106.437%
IRLAB Therapeutics AB (publ) 61.35 Million SEK 77.158%
Isofol Medical AB (publ) 19.16 Million SEK 26.868%
I-Tech AB 16.2 Million SEK 13.514%
Hansa Biopharma AB (publ) 1.18 Billion SEK 98.818%
Cyxone AB (publ) 4.69 Million SEK -198.573%
ExpreS2ion Biotech Holding AB (publ) 13.32 Million SEK -5.155%
Biosergen AB 5.08 Million SEK -175.615%
Cantargia AB (publ) 54.97 Million SEK 74.504%
NextCell Pharma AB 13.68 Million SEK -2.381%
Xspray Pharma AB (publ) 71.85 Million SEK 80.494%
Elicera Therapeutics AB (publ) 13.77 Million SEK -1.768%
Nanologica AB (publ) 79.32 Million SEK 82.333%
SynAct Pharma AB 51.83 Million SEK 72.962%
Annexin Pharmaceuticals AB (publ) 7.94 Million SEK -76.311%
Stayble Therapeutics AB (publ) 5.19 Million SEK -169.782%
LIDDS AB (publ) 3.75 Million SEK -273.136%
Lipum AB (publ) 7.53 Million SEK -85.925%
BioInvent International AB (publ) 90.45 Million SEK 84.506%
Alzinova AB (publ) 9.33 Million SEK -50.198%
Oncopeptides AB (publ) 181.59 Million SEK 92.282%
Pila Pharma AB (publ) 1.79 Million SEK -681.215%
Guard Therapeutics International AB (publ) 18.49 Million SEK 24.219%
Scandinavian ChemoTech AB (publ) 3.83 Million SEK -265.164%
Simris Alg AB (publ) 148.93 Million SEK 90.59%
Diamyd Medical AB (publ) 71.11 Million SEK 80.293%
Xbrane Biopharma AB (publ) 482.17 Million SEK 97.093%
Ascelia Pharma AB (publ) 12.74 Million SEK -9.973%
Diagonal Bio AB (publ) 7.26 Million SEK -93.044%